Biological activity of probable/possible high-risk human papillomavirus types in cervical cancer

International Journal of Cancer

Volumn 132, Issue 1, 2013, Pages 63-71

  Halec, Gordana ^a,b   Schmitt, Markus ^a   Dondog, Bolormaa ^a,c   Sharkhuu, Enkhtuya ^d   Wentzensen, Nicolas ^e   Gheit, Tarik ^c   Tommasino, Massimo ^c   Kommoss, Friedrich ^f   Bosch, Franz X ^b   Franceschi, Silvia ^c   Clifford, Gary ^c   Gissmann, Lutz ^a,g   Pawlita, Michael ^a  

^a GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

^b UNIVERSITY OF HEIDELBERG   (Germany)

^c INTERNATIONAL AGENCY FOR RESEARCH ON CANCER   (France)

^d National Cancer Centre of Mongolia (NCCM)   (Mongolia)

^e NATIONAL CANCER INSTITUTE   (United States)

^f Institute of Pathology   (Germany)

^g KING SAUD UNIVERSITY   (Saudi Arabia)

Author keywords

cervical cancer; E6*I; human papillomavirus; mRNA; p16INK4a

Indexed keywords

CYCLIN DEPENDENT KINASE INHIBITOR 2A; MESSENGER RNA; PROTEIN E6; PROTEIN P53; RETINOBLASTOMA PROTEIN; VIRUS DNA;

ADULT; AGED; ARTICLE; BREAST BIOPSY; CANCER RISK; E6 GENE; FEMALE; GENE EXPRESSION REGULATION; GENE OVEREXPRESSION; GENOTYPE; HUMAN; HUMAN PAPILLOMAVIRUS TYPE 26; HUMAN PAPILLOMAVIRUS TYPE 66; HUMAN PAPILLOMAVIRUS TYPE 70; HUMAN PAPILLOMAVIRUS TYPE 82; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MOLECULAR CLONING; PAPILLOMAVIRUS INFECTION; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; RNA SPLICING; SENSITIVITY AND SPECIFICITY; UTERINE CERVIX CANCER; VIRUS CARCINOGENESIS; VIRUS GENE; VIRUS TRANSCRIPTION; WART VIRUS;

ADULT; AGED; DNA, VIRAL; FEMALE; GENOTYPE; HUMANS; IMMUNOHISTOCHEMISTRY; MIDDLE AGED; NEOPLASM PROTEINS; PAPILLOMAVIRIDAE; PAPILLOMAVIRUS INFECTIONS; RETINOBLASTOMA PROTEIN; RISK FACTORS; RNA SPLICE SITES; RNA, MESSENGER; RNA, VIRAL; TRANSCRIPTION, GENETIC; TUMOR SUPPRESSOR PROTEIN P53; UTERINE CERVICAL NEOPLASMS;

EID: 84868204607     PISSN: 00207136     EISSN: 10970215     Source Type: Journal    
DOI: 10.1002/ijc.27605     Document Type: Article

References (40)

1. Walboomers JM, Jacobs MV, Manos MM, et al. Human papillomavirus is a necessary cause of invasive cervical cancer worldwide. J Pathol 1999; 189: 12-9.
2. zur Hausen H,. Papillomaviruses and cancer: from basic studies to clinical application. Nat Rev Cancer 2002; 2: 342-50.
3. Schiffman M, Clifford G, Buonaguro FM,. Classification of weakly carcinogenic human papillomavirus types: addressing the limits of epidemiology at the borderline. Infect Agent Cancer 2009; 4: 8.
4. Clifford GM, Howell-Jones R, Franceschi S,. Judging the carcinogenicity of human papillomavirus types by single/multiple infection ratio in cervical cancer. Int J Cancer 2011; 129: 1792-4.
5. de Sanjose S, Quint WG, Alemany L, et al. Human papillomavirus genotype attribution in invasive cervical cancer: a retrospective cross-sectional worldwide study. Lancet Oncol 2010; 11: 1048-56.
6. Li N, Franceschi S, Howell-Jones R, Snijders PJ, et al. Human papillomavirus type distribution in 30,848 invasive cervical cancers worldwide: variation by geographical region, histological type and year of publication. Int J Cancer 2011; 128: 927-35.
7. IARC. Human papillomaviruses. IARC Monogr Eval Carcinog Risks Hum 2011; 100B: 1-475. A review of human carcinogensa-part B: biological agents, vol. 100B, 2011.
8. Smotkin D, Prokoph H, Wettstein FO,. Oncogenic and nononcogenic human genital papillomaviruses generate the E7 mRNA by different mechanisms. J Virol 1989; 63: 1441-7.
9. Stacey SN, Jordan D, Snijders PJ, et al. Translation of the human papillomavirus type 16 E7 oncoprotein from bicistronic mRNA is independent of splicing events within the E6 open reading frame. J Virol 1995; 69: 7023-31.
10. Chow LT, Nasseri M, Wolinsky SM, et al. Human papillomavirus types 6 and 11 mRNAs from genital condylomata acuminata. J Virol 1987; 61: 2581-8.
11. Smotkin D, Wettstein FO,. Transcription of human papillomavirus type 16 early genes in a cervical cancer and a cancer-derived cell line and identification of the E7 protein. Proc Natl Acad Sci U S A 1986; 83: 4680-4.
12. Schneider-Gadicke A, Schwarz E,. Different human cervical carcinoma cell lines show similar transcription patterns of human papillomavirus type 18 early genes. EMBO J 1986; 5: 2285-92.
13. Lungu O, Crum CP, Silverstein S,. Biologic properties and nucleotide sequence analysis of human papillomavirus type 51. J Virol 1991; 65: 4216-25.
14. Snijders PJ, van den Brule AJ, Schrijnemakers HF, et al. Human papillomavirus type 33 in a tonsillar carcinoma generates its putative E7 mRNA via two E6* transcript species which are terminated at different early region poly(A) sites. J Virol 1992; 66: 3172-8.
15. Nakagawa S, Yoshikawa H, Yasugi T, et al. Ubiquitous presence of E6 and E7 transcripts in human papillomavirus-positive cervical carcinomas regardless of its type. J Med Virol 2000; 62: 251-8.
16. Sotlar K, Stubner A, Diemer D, et al. Detection of high-risk human papillomavirus E6 and E7 oncogene transcripts in cervical scrapes by nested RT-polymerase chain reaction. J Med Virol 2004; 74: 107-16.
17. von Knebel Doeberitz M, Rittmuller C, zur Hausen H, et al. Inhibition of tumorigenicity of cervical cancer cells in nude mice by HPV E6-E7 anti-sense RNA. Int J Cancer 1992; 51: 831-4.
18. Munger K, Scheffner M, Huibregtse JM, et al. Interactions of HPV E6 and E7 oncoproteins with tumour suppressor gene products. Cancer Surv 1992; 12: 197-217.
19. Scheffner M, Werness BA, Huibregtse JM, et al. The E6 oncoprotein encoded by human papillomavirus types 16 and 18 promotes the degradation of p53. Cell 1990; 63: 1129-36.
20. Munger K, Werness BA, Dyson N, et al. Complex formation of human papillomavirus E7 proteins with the retinoblastoma tumor suppressor gene product. EMBO J 1989; 8: 4099-105.
21. Howley PM, Munger K, Romanczuk H, et al. Cellular targets of the oncoproteins encoded by the cancer associated human papillomaviruses. Princess Takamatsu Symp 1991; 22: 239-48.
22. Scheffner M, Munger K, Huibregtse JM, et al. Targeted degradation of the retinoblastoma protein by human papillomavirus E7-E6 fusion proteins. EMBO J 1992; 11: 2425-31.
23. Klaes R, Friedrich T, Spitkovsky D, et al. Overexpression of p16(INK4A) as a specific marker for dysplastic and neoplastic epithelial cells of the cervix uteri. Int J Cancer 2001; 92: 276-84.
24. Chung JY, Braunschweig T, Williams R, et al. Factors in tissue handling and processing that impact RNA obtained from formalin-fixed, paraffin-embedded tissue. J Histochem Cytochem 2008; 56: 1033-42.
25. Molden T, Kraus I, Skomedal H, et al. PreTect HPV-Proofer: real-time detection and typing of E6/E7 mRNA from carcinogenic human papillomaviruses. J Virol Methods 2007; 142: 204-12.
26. Dockter J, Schroder A, Eaton B, et al. Analytical characterization of the APTIMA HPV Assay. J Clin Virol 2009; 45 (Suppl 1): S39-47.
27. Schmitt M, Dalstein V, Waterboer T, et al. Diagnosing cervical cancer and high-grade precursors by HPV16 transcription patterns. Cancer Res 2010; 70: 249-56.
28. Kleter B, van Doorn LJ, ter Schegget J, et al. Novel short-fragment PCR assay for highly sensitive broad-spectrum detection of anogenital human papillomaviruses. Am J Pathol 1998; 153: 1731-9.
29. Smeets SJ, Hesselink AT, Speel EJ, et al. A novel algorithm for reliable detection of human papillomavirus in paraffin embedded head and neck cancer specimen. Int J Cancer 2007; 121: 2465-72.
30. Dondog B, Clifford GM, Vaccarella S, et al. Human papillomavirus infection in Ulaanbaatar, Mongolia: a population-based study. Cancer Epidemiol Biomarkers Prev 2008; 17: 1731-8.
31. de Koning MN, Quint WG, Pirog EC,. Prevalence of mucosal and cutaneous human papillomaviruses in different histologic subtypes of vulvar carcinoma. Mod Pathol 2008; 21: 334-44.
32. Schmitt M, Bravo IG, Snijders PJ, et al. Bead-based multiplex genotyping of human papillomaviruses. J Clin Microbiol 2006; 44: 504-12.
33. Schmitt M, Dondog B, Waterboer T, et al. Homogeneous amplification of genital human alpha papillomaviruses by PCR using novel broad-spectrum GP5+ and GP6+ primers. J Clin Microbiol 2008; 46: 1050-9.
34. Schmitt M, Dondog B, Waterboer T, et al. Abundance of multiple high-risk human papillomavirus (HPV) infections found in cervical cells analyzed by use of an ultrasensitive HPV genotyping assay. J Clin Microbiol 2010; 48: 143-9.
35. Gheit T, Landi S, Gemignani F, et al. Development of a sensitive and specific assay combining multiplex PCR and DNA microarray primer extension to detect high-risk mucosal human papillomavirus types. J Clin Microbiol 2006; 44: 2025-31.
36. Insinga RP, Liaw KL, Johnson LG, et al. A systematic review of the prevalence and attribution of human papillomavirus types among cervical, vaginal, and vulvar precancers and cancers in the United States. Cancer Epidemiol Biomarkers Prev 2008; 17: 1611-22.
37. Chimeddorj B, Pak CY, Damdin A, et al. Distribution of HPV-16 intratypic variants among women with cervical intraepithelial neoplasia and invasive cervical cancer in Mongolia. Asian Pac J Cancer Prev 2008; 9: 563-8.
38. Hiller T, Poppelreuther S, Stubenrauch F, et al. Comparative analysis of 19 genital human papillomavirus types with regard to p53 degradation, immortalization, phylogeny, and epidemiologic risk classification. Cancer Epidemiol Biomarkers Prev 2006; 15: 1262-7.
39. Mesplede T, Gagnon D, Bergeron-Labrecque F, et al. P53-degradation activity, expression and subcellular localization of E6 proteins from 29 human papillomavirus genotypes. J Virol 2012; 86: 94-107.
40. Quint W, Jenkins D, Molijn A, et al. One virus one lesiona-individual components of CIN lesions contain a specific HPV type. J Pathol 2012; 227: 62-71.